Pfizer posts $15.03 billion in second quarter revenue and lifts the low end of its full year outlook

Pfizer reported second quarter results above analyst expectations on Tuesday 4 August 2026. According to CNBC, revenue came in at $15.03 billion against a forecast of $14.41 billion, and adjusted earnings per share were 77 cents versus 68 cents expected. Revenue rose about 3% from the same period of 2025.

The company raised the low end of its full year revenue outlook from $59.5 billion to $60.5 billion, keeping the top of the range at $62.5 billion, while cutting its full year forecast for Covid products from about $5 billion to $4 billion. Sales of the blood thinner Eliquis rose 19% to $2.43 billion.

Pfizer booked a net loss of $248 million, or 4 cents a share, for the quarter, largely reflecting $4.3 billion in non cash intangible asset impairments. It also announced an additional $2.5 billion of savings across two cost cutting programmes running to 2029, and reiterated full year adjusted profit guidance of $2.80 to $3.00 per share.